ArticleBMC pulmonary medicine2026
Clinical and prognostic characteristics of stable bronchiectasis in adults with chronic Pseudomonas aeruginosa infection: a prospective cohort study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBacterial infection and colonization are gradually associated with disease severity and prognosis in bronchiectasis. The impact of chronic Pseudomonas aeruginosa (PA) infection on the clinical features and disease progression in stable bronchiectasis remains unclear. This study aims to investigate the association between chronic PA infection and lung function as well as prognosis in stable bronchiectasis.
methodsThis prospective cohort study enrolled patients with stable bronchiectasis, with or without chronic PA infection, in Shanghai between January 2020 and December 2023. We compared the baseline data including clinical characteristics, laboratory findings, and lung function. During follow-up until December 2024, we monitored lung function at the first follow-up visit and recorded the time to first exacerbation.
resultsA total of 391 patients with stable bronchiectasis were enrolled, including 118 (30.2%) with chronic PA infection. These patients showed significantly higher age, BMI < 18.5 kg/m2, disease duration, affected lobes, modified Reiff score, BSI, E-FACED score, exacerbations and related hospitalizations in the prior year, resolved chronic PA infection, purulent sputum, cough, wheezes, crackles, CRP, and CD4⁺T cell counts < 500. Conversely, BMI, other bacterial colonization, and CD4⁺T cell was lower in chronic PA infection group. Among 210 patients who completed at least one lung function follow-up, forced vital capacity (FVC), FVC%predicted, forced expiratory volume in 1 s (FEV1), FEV1%predicted, and FEV₁/FVC ratio at the first follow-up were significantly lower than baseline. After propensity score matching, 87 patients (32 chronic PA infection, 55 without chronic PA infection) were included. The chronic PA infection group showed significantly greater declines in ΔFEV1 and ΔFEV1/FVC ratio. Survival analysis revealed a significantly shorter median time to first exacerbation in patients with chronic PA infection than in those without (202 days vs. 328 days). Chronic PA infection was associated with exacerbation of bronchiectasis (HR = 1.571; 95%CI: 1.014–2.432).
conclusionChronic PA infection in stable bronchiectasis was associated with high disease severity, accelerated lung function decline and increased exacerbation risk. These results suggested that chronic PA infection contributes to the progression of bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.